3 Top Biotech Stocks for Spring 2021
What do playing right field in baseball, deep-sea fishing, and investing in small biotech stocks have in common? Long periods of boredom followed by moments of intense drama. For shareholders of bluebird bio (NASDAQ: BLUE), Sage Therapeutics (NASDAQ: SAGE), and Trillium Therapeutics (NASDAQ: TRIL), spring announcements may pierce the monotony with updates on key drug development programs. After those stocks' recent struggles, management teams and shareholders are hoping the news will get their share prices moving back toward previous highs.
Image source: Getty Images.
Bluebird has been focused on gene therapies for severe and genetic diseases since its founding in 2010. The company went public in 2013 shortly after signing a collaboration agreement with Celgene. The stock peaked 900% higher in 2018 when the two companies agreed to co-develop and co-promote Bluebird's treatment for multiple myeloma.
Source Fool.com
